Not provided
Not provided
Not provided
Not provided
Not provided
Department feasibility
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| AtriCure, Inc. | INDUSTRY |
Not provided
Not provided
Not provided
Not provided
Pilot, randomized, unblinded, feasibility and proof of concept clinical trial randomizing 50 patients in a 1:1 ratio to hybrid ablation or catheter ablation
To determine if a hybrid convergent ablation procedure with atrial appendage clip is superior to catheter ablation in the management of heart failure patients with persistent and longstanding persistent AF.
Hypothesis: Hybrid convergent ablation procedure with atrial appendage clip is superior to catheter ablation in the management of heart failure patients with persistent and longstanding persistent AF in terms of mortality and worsening heart failure, AF rhythm control and improvement in LVEF, quality of life, and 6-minute walk distance.
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Control | Active Comparator | Catheter ablation including PVI and posterior wall ablation |
|
| Intervention | Experimental | Convergent ablation Surgical epicardial ablation/ LAA clip/ ablation of ligament of Marshall Catheter Ablation including PVI and posterior wall ablation |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Convergent ablation | Procedure | Staged hybrid ablation with CONVERGENT epicardial ablation with ablation of the ligament of Marshall and left atrial appendage clip, followed in second stage by endocardial catheter ablation including pulmonary vein isolation and posterior wall ablation with roof and inferior posterior lines in addition to targeting and touching up any areas with signals at the posterior wall |
| Measure | Description | Time Frame |
|---|---|---|
| Composite of Major Adverse Event Rate after blanking period post procedure | Major Adverse Events consist of death from cardiovascular causes, worsening of heart failure defined as hospitalization, visits for IV diuresis or escalation to advanced heart failure therapies; need for continuation of AADs or redo ablation for recurrent arrhythmias beyond the blanking period. | Up to 2 years |
| Measure | Description | Time Frame |
|---|---|---|
| AF burden | Percentage of AF out of the total monitored time | up to 2 years |
| Death from cardiovascular causes | Occurrence of death from cardiovascular causes |
Not provided
Inclusion Criteria:
Subjects must meet all of the following criteria:
Exclusion Criteria:
Subjects must meet none of the criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Ayman Hussein, MD | The Cleveland Clinic | Principal Investigator |
Not provided
| ID | Term |
|---|---|
| D001281 | Atrial Fibrillation |
| D006333 | Heart Failure |
| ID | Term |
|---|---|
| D001145 | Arrhythmias, Cardiac |
| D006331 | Heart Diseases |
| D002318 | Cardiovascular Diseases |
| D010335 | Pathologic Processes |
Not provided
Not provided
| ID | Term |
|---|---|
| D017115 | Catheter Ablation |
| ID | Term |
|---|---|
| D000078703 | Radiofrequency Ablation |
| D000078702 | Radiofrequency Therapy |
| D013812 | Therapeutics |
| D055011 | Ablation Techniques |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
|
| Catheter ablation | Procedure | Pulmonary vein isolation using commercially available catheters; including pulmonary vein isolation and posterior wall ablation with roof and inferior posterior lines in addition to targeting and touching up any areas with signals at the posterior wall |
|
| up to 2 years |
| Worsening of Heart Failure | Occurrence of worsening of heart failure defined as: hospitalization, visits for IV diuresis or escalation to advanced heart failure therapies | up to 2 years |
| Need for continuation of Antiarrhythmic drug(s) beyond the blanking period | Occurrence of worsening of heart failure defined as: hospitalization, visits for IV diuresis or escalation to advanced heart failure therapies | 3 month post procedure up to 2 years |
| Redo ablation beyond the blanking period | Occurrence of arrhythmia requiring redo ablation | 3 month post procedure up to 2 years |
| Total number of cardiovascular hospitalizations | Number of cardiovascular-related hospitalizations | Up to 2 years |
| Recurrence of AF lasting more than 30 seconds | Number of occurrence of AF lasting more than 30 seconds | Up to 2 years |
| Change in distance walked in 6-minute walk test | Change in meters walked in 6-minute walk test compared to baseline | up to 2 years |
| Change in MLHF Quality of Life | Based on composite score (0-105). Each item is scored in a 6-point Likert Scale (0 = none to 5 = very much), thus the total score could range from 0 to 105, with higher scores indicating more significant impairment in health-related quality of life. Score is compared to baseline. | up to 2 years |
| Change in EF during trial period | EF percentage change compared to baseline | up to 2 years |
| All-cause mortality | Occurrence of death from all-cause | up to 2 years |
| Unplanned hospitalization due to cardiovascular reasons | Occurrence of unplanned hospitalizations for cardiovascular reasons | up to 2 years |
| Worsening heart failure requiring unplanned hospitalization or escalation to advanced heart failure therapies | Occurrence of worsening heart failure requiring unplanned hospitalization or escalation to advanced heart failure therapies requiring: LV mechanical assist devices, transplant, intravenous inotropes | up to 2 years |
| Cerebrovascular accidents | Occurrence of cardiovascular accidents | up to 2 years |
| D013568 |
| Pathological Conditions, Signs and Symptoms |
| D013514 |
| Surgical Procedures, Operative |